ASO specifically targeting LINC02568 significantly inhibits ER+ breast tumor growth, and combination therapy with endocrine therapy drug, such as tamoxifen and ICI, exhibited synergistic effects. This evidence concerns the gene ESR1 and breast neoplasm.